CIANCETTA, Antonella
 Distribuzione geografica
Continente #
NA - Nord America 1.403
AS - Asia 317
EU - Europa 303
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 2.027
Nazione #
US - Stati Uniti d'America 1.394
SG - Singapore 148
IT - Italia 101
CN - Cina 89
TR - Turchia 52
PL - Polonia 38
UA - Ucraina 38
GB - Regno Unito 36
DE - Germania 32
SE - Svezia 21
ID - Indonesia 19
FI - Finlandia 17
CA - Canada 9
CZ - Repubblica Ceca 8
BE - Belgio 5
HK - Hong Kong 4
AT - Austria 2
KR - Corea 2
LT - Lituania 2
RU - Federazione Russa 2
AU - Australia 1
CL - Cile 1
EU - Europa 1
FR - Francia 1
IR - Iran 1
NZ - Nuova Zelanda 1
TW - Taiwan 1
VN - Vietnam 1
Totale 2.027
Città #
Santa Clara 181
Chandler 138
Fairfield 138
Singapore 120
Ashburn 118
Ann Arbor 93
Houston 91
Woodbridge 85
Ferrara 58
Jacksonville 54
Wilmington 50
Seattle 49
Princeton 46
Cambridge 44
Warsaw 38
Izmir 25
Shanghai 24
Jakarta 19
San Diego 18
Beijing 12
Washington 12
London 11
Nanjing 11
Boardman 9
Falls Church 9
Brno 8
Helsinki 8
Los Angeles 7
Toronto 7
Changsha 6
Brussels 5
Chicago 5
Milan 5
Redmond 5
Ferrara di Monte Baldo 4
Hong Kong 4
New York 4
Norwalk 4
Addison 3
Bologna 3
Chiswick 3
Falkenstein 3
Jiaxing 3
Jinan 3
Zhengzhou 3
Bremen 2
Hebei 2
Kilburn 2
Kunming 2
Nanchang 2
Novara 2
Tianjin 2
Venice 2
Yeongdeungpo-gu 2
Brentford 1
Camerino 1
Changchun 1
Chongqing 1
Dearborn 1
Dong Ket 1
Dunedin 1
Forest City 1
Frankfurt am Main 1
Guangzhou 1
Hangzhou 1
Hounslow 1
Indiana 1
Islington 1
Kashan 1
Lanzhou 1
Longare 1
Mestre 1
Mountain View 1
Munich 1
Novokuznetsk 1
Ottawa 1
Padova 1
Palo del Colle 1
Piscataway 1
San Lazzaro di Savena 1
Saskatoon 1
Shenyang 1
Shijiazhuang 1
Southfield 1
Southwark 1
Taipei 1
Tappahannock 1
Vienna 1
Wandsworth 1
Totale 1.599
Nome #
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 160
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 155
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 133
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 130
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 126
null 118
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 93
null 90
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 82
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 56
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 55
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 41
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 41
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 39
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 37
A QM/MM study of the binding of RAPTA ligands to cathepsin B 36
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 35
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 34
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 33
Aquaporin inhibition by gold(III) compounds: New insights 32
Activation of carboplatin by chloride ions: a theoretical investigation 29
Advances in Computational Techniques to Study GPCR-Ligand Recognition 29
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 29
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 28
Activation of carboplatin by carbonate: A theoretical investigation 27
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 27
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 24
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 24
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 23
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 23
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 22
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 22
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 21
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 19
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 19
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 18
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 18
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 18
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 17
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 15
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 13
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 13
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 12
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 12
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 12
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 12
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 12
Implementing the “Best Template Searching” tool into Adenosiland platform 11
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 11
Polypharmacology of conformationally locked methanocarba nucleosides 11
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 10
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 10
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 7
In silico 3D modeling of binding activities 7
Enhancing torsional sampling using fully adaptive simulated tempering 5
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 4
“Protein-ligand docking: virtual screening and applications to drug discovery” 4
Totale 2.144
Categoria #
all - tutte 21.530
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 921
Totale 22.451


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020120 0 0 0 0 0 27 20 19 19 17 9 9
2020/2021221 13 7 15 20 7 24 7 25 16 45 32 10
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/2025397 19 21 98 23 137 99 0 0 0 0 0 0
Totale 2.144